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This review provides an overview of the state and future directions of
development and pathology in the craniofacial complex in the context of
Cranial Neural Crest Cells (CNCC). CNCC are a multipotent cell population
that is largely responsible for forming the vertebrate head. We focus on
findings that have increased the knowledge of gene regulatory networks and
molecular mechanisms governing CNCC migration and the participation of
these cells in tissue formation. Pathology due to aberrant migration or cell
death of CNCC, termed neurocristopathies, is discussed in addition to
craniosynostoses. Finally, we discuss tissue engineering applications that take
advantage of recent advancements in genome editing and the multipotent
nature of CNCC. These applications have relevance to treating diseases due
directly to the failure of CNCC, and also in restoring tissues lost due to a
variety of reasons.
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What are Neural Crest Cells and in Particular
Cranial Neural Crest Cells?
Neural crest cells (NCC) are a transient group of multipo-
tent cells that are specified along the dorsal aspect of the
neural tube, delaminate from the neural tube via an
epithelial-mesenchymal transition (EMT), migrate in
streams along their body segment, and subsequently dif-
ferentiate under the guide of many signaling pathways
throughout their journey. A subset of NCC, termed cranial
neural crest cells (CNCC), delaminate from the more ante-
rior portions of the folded neural tube and migrate in a
single wave to give rise to many vertebrate head struc-
tures, including a majority of the skull and face (Le
Douarin and Kalcheim, 1999; Mishina and Snider, 2014).
As the CNCC are induced and begin to migrate, they are
influenced by their physical contact with one another and
also respond to reciprocal signals sent to one another.
Local molecular gradients are also known to play a role in
their migration (Theveneau and Mayor, 2012).
Initial investigations into the nature of NCC migration
took advantage of an avian model consisting of Quail–
Chick (QC) chimeras. This model allowed for easy visual-
ization of NCC, based on chromosomal differences visible
during interphase between the two species (Le Douarin,
1973). QC chimera experiments have formed an experi-
mental basis to test which genes and gene products effect
CNCC behavior and ability to form skeletogenic compo-
nents of the craniofacial complex. For example, Fgf8 is
indispensable for the survival of cells that make up the
first branchial arch, as shown by the fact that knock down
of this gene in the ectoderm and neuroepithelium results
in a lack of craniofacial structures due to a failure of CNCC
migration. This phenotype can be rescued by exogenous
FGF8 application which promotes CNCC proliferation
(Creuzet et al., 2004). Today, a variety of model systems,
including turtle and lamprey, but mainly mice and avian
models, are used to study CNCC (Santagati and Rijli, 2003;
Green and Bronner, 2014; Nagashima et al., 2014; Young
et al., 2014).
A number of molecular events must take place to
orchestrate this induction, migration, and eventual fate
determination of these multipotent cells (Trainor, 2013).
Alterations in any of these processes can have a devastating
array of effects on the developing embryo. In particular, the
cranium and face are involved in a disproportionate num-
ber of birth defects, nearly a third, likely due to the intrica-
cies involved in the genesis of a diverse collection of tissues
present in a relatively small volume. Extensive collections
of genes have been identified or are theorized to take part
during the normal development of the craniofacial complex.
A recent study reported collecting chick embryos electropo-
rated with the Sox10e2:eGFP to mark migrating CNCC, and
then GFP1CNCC were sorted via FACS. Subsequent exten-
sive bioinformatic analysis of the transcritptome of migrat-
ing CNCC revealed SOX9 and ETS1 gene expression may be
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critically important to kick off a cascade of events that
helps initiate and then guide CNCC along their migration
(Simoes-Costa et al., 2014).
How do NCC Begin Their Migration, and What
Structures do They Make?
Several signaling pathways have been shown to be
involved in the physiologic and pathologic behavior of
NCC, such as the FGF, WNT, TGFb, and BMP pathways
(Mishina and Snider, 2014). Many animal models have
been generated to investigate each of these pathways
that have been shown to be relevant to human disease.
Here, we focus on the BMP and TGFb signaling pathways
and relate advances in knowledge of those pathways in
CNCC to increased understanding of craniofacial
development.
CNCC are initially specified at the neural plate border
and then migrate from the dorsal portion of the neural
tube to populate developing cranial structures. An EMT is
necessary prior to CNCC commencing their migration.
LSox5, p53, and ETS1 are expressed by CNCC (Perez-Alcala
et al., 2004; Theveneau et al., 2007; Rinon et al., 2011). It
is interesting, and also important for potential therapeutic
measures, that apoptosis mediated by p53 is required for
normal outcomes in CNCC migration (Rinon et al., 2011).
BMP, bone morphogenetic protein, signaling is important
to help regulate the cell cycle, which is important for
induction and EMT to occur properly (Burstyn-Cohen
et al., 2004). MSX2, a downstream target of the BMP sig-
naling pathway, plays a role in the development of the cra-
niofacial complex and also in the apoptosis of CNCC. It has
been demonstrated that BMP4 is necessary to induce apo-
ptosis in CNCC (Graham et al., 1994; Winograd et al.,
1997; Takahashi et al., 2001).
The first evidence that the TGFb signaling pathway is
quite important during craniofacial development, in par-
ticular in palatogenesis, came with the knowledge that
global knock out of the TGF-b3 gene results in cleft pal-
ate in mice (Kaartinen et al., 1995). Tissue specific inter-
actions resulting from TGFb signaling were further
elucidated with the use of epithelium specific Keratin14-
Cre and NCC specific Wnt1-Cre. Tissue specific deletions
using mice with the type 1 TGFb receptor flanked by
loxP sites, Alk5fl/fl, revealed that both Wnt1-Cre/Alk5fl/fl
mice as well as K14-Cre/Alk5fl/fl displayed cleft palate;
however, the deletion of Alk5 in NCC also revealed
pathology of the nasal cavity as well as the skull vault
(Dudas et al., 2006). Although the underlying mechanism
of cleft palate formation between the K14-Cre/Alk5fl/fl
and Wnt1-Cre/Alk5fl/fl may be different, as suggested by
increased proliferation and cell death in the mesenchyme
of the Wnt1-Cre/Alk5fl/fl mice, the indispensible nature of
TGFb signaling within both ectodermal and ectomesen-
chymal cell types during normal craniofacial develop-
ment was strongly suggested.
Using Wnt1-Cre to delete a type two TGFb receptor
Tgfbr2, another component in the TGFb signaling pathway,
results in craniofacial development with a phenotype par-
tially overlapping that of the Wnt1-Cre/Alk5fl/fl mice. When
mice carrying the Wnt1-Cre transgene are bred with
Tgfbr2fl/fl mice, the resulting pups have a cleft palate due
to decreased proliferation of CNCC derived palatal mesen-
chyme, as well as severe skull malformation (Ito et al.,
2003). The similarity of the skull vault malformation
between Wnt1-Cre/Tgfbr2fl/fl and Wnt1-Cre/Alk5 reveals
potential redundancies in TGFb receptor function in CNCC
during skull vault formation.
As Osterix-Cre (Osx-Cre) is expressed by osteoblasts as
well as odontoblasts, Tgfbr2fl/fl mice have also been bred
with mice carrying the Osx-Cre transgene to investigate
the function of Tgfbr2 in cells critical to mineralized tissue
formation. Osteoblasts are critical to cranial bone forma-
tion and odontoblasts form a majority of the molar tooth
root, so using Osx-Cre deletes Tgfbr2 in the skeletogenic
progeny of CNCC, thus testing the effects of TGFb signaling
as CNCC become more committed. The palate of Osx-Cre/
Tgfbr2fl/fl mice develops normally, whereas the molar root
formation and dental mesenchyme are adversely affected
(Wang et al., 2013). The absence of a drastic skull pheno-
type found in Osx-Cre/Tgfbr2fl/fl, compared to those
described in Wnt1-Cre/Tgfbr2fl/fl, and Wnt1-Cre/Alk5, indi-
cates that TGFb signaling in CNCC is required during early
skull formation, but becomes dispensable in this process
as CNCC continue to differentiate into more committed
cells.
Together, these studies underscore the effect of spatio-
temporal expression of TGFb signaling components in
CNCC and their derivatives during craniofacial develop-
ment. These findings also reinforce the notion that the
promoter used to drive Cre expression can result in infor-
mation critical to dissecting out which combinations of
genes expressed by unique cell populations are indispensi-
ble for a given tissues formation. These TGFb pathway
studies in mice have been shown to be a good model for
human disease. The finding of 10 families presenting with
craniofacial anomalies and concomitant mutations in either
TGFbR1 or TGFbR2 provided strong support that TGFb sig-
naling is critical for craniofacial development in humans
as well (Loeys et al., 2005).
Which Birth Defects in Particular are Rooted in
CNCC Defects?
Many birth defects often result in growth and develop-
mental delays at sites in the craniofacial complex as well
as involving other anatomical locations. The broad pheno-
typic display presented in these syndromes obviates the
difficulty in ascertaining which findings are primary and
which arise secondarily to the etiopathology. For example,
aberrant mandibular growth may persist for years in
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several syndromes which have a broad phenotypic display
present from birth (Boutros et al., 2007). Although it is
desirable to move away from discussing syndromes based
on the names of the discoverer, and instead refer to them
by a more informative name indicative of either the etiol-
ogy or phenotype, eponyms are referred to here to be
complete. Improper migration or reduced survival of CNCC
is implicated in several syndromes and congenital condi-
tions termed neurocristopathies. Craniofacial anomalies
are seen in neurocristopathies, such as DiGeorge syn-
drome, Waardenburg syndrome (WS), CHARGE syndrome,
Treacher Collins syndrome (TCS), and craniofacial microso-
mia (CFM). (Table 1 provides a summary of neurocristopa-
thies with additional information.)
DiGeorge (velocardiofacial) syndrome is a classical
example of a disease due to changes in CNCC migration
due to genetic mutation. The 22q11.2 deletion syndrome
(22q11DS) occurs in approximately 1 in 4000 births and
typically includes a wide range of defects involving the
initial formation and subsequent development of the
craniofacial complex. In particular, cardiac defects,
cognitive-behavioral problems, speech-language disorders,
velopharyngeal insufficiency (VPI), and dysmorphic facial
appearance have been well documented. 22q11DS is rec-
ognized as the most frequently occurring syndrome associ-
ated with VPI and anomalies affecting the palate
(Shprintzen et al., 1978; Bassett et al., 2011). Hemizygosity
at the TBX1 gene locus is believed to underlie the pathol-
ogy, although other genes are deleted when this portion of
chromosome 22 is deleted (Papangeli and Scambler,
2013).
WS is a neurocristopathy with heterogeneous presenta-
tion; four forms have been identified. The most common
findings include hypopigmentation of the eyes, isolated
patches of white hair on the anterior scalp, and sensori-
neural hearing loss, ranging from total deafness to a pro-
gressive loss of hearing. Mutations in SOX10 have been
implicated to be a potential cause of the hypopigmentation
of the skin, hair, and eyes commonly found in patients
with WS (Hou and Pavan, 2008). In support of this notion,
mice haploinsufficient for Sox10 show similar symptoms,
including isolated patches of white fur reminiscent of the
hypopigmentation found in WS patients (Southard-Smith
et al., 1999). A labor-intensive mutagenesis screening of
mice haploinsufficient for Sox10 has also been used to
identify genomic loci that exacerbate the hypopigmenta-
tion phenotype. Three new loci were identified as poten-
tial modifiers of Sox10. A compound heterozygote formed
between Sox10 and one of the modifiers led to a decrease
in NCC ability to form melanoblasts (Matera et al., 2008).
Several other genes have also been identified that lead to
specific forms of WS (Pingault et al., 2010).
CHARGE syndrome is diagnosed by the appearance of
several distinct features. All of the features may not be
present, but CHARGE usually presents with the following
findings: coloboma of the eye, choanal atresia, heart
defects, retardation of growth, genital malformations, and
abnormal ears. CHD7 mutations have been identified as
causes of the syndrome (Lalani et al., 2006)
TCS results from a failure of migration of CNCC. Under-
developed facial bones resulting from autosomal dominant
mutations in the TCOF1 gene phenotypically characterize
TCS. A mouse model haploinsufficient for Tcof1 and reca-
pitulating the characteristics of TCS has been generated.
This allowed the demonstration that lack of formation and
proliferation of CNCC were responsible for the craniofacial
phenotype (Dixon et al., 2006). Although there is much
work yet to be done, showing that inhibition of p53, either
with a chemical inhibitor or through genetic deletion of a
p53 allele, rescues the TCS phenotype in mice was a huge
step toward being able to treat this disease clinically
(Jones et al., 2008). Interestingly, the TCS phenotype was
corrected without resolving the lack of ribosome biogene-
sis observed, which suggests that it makes sense to target
downstream events in the treatment of neurocristopathies
resulting from increased cell death of CNCC.
CFM is a congenital disorder of the face with an esti-
mated prevalence of 1:3500 to 1:5500. CFM is characterized
by asymmetric underdevelopment of structures originating
from the first and second branchial arches, including the
orbit, mandible, nerve, soft tissue, and muscles of mastica-
tion. Goldenhar syndrome is one of the forms of CFM and
was first described in the 1950s. Goldenhar syndrome
presents with the same constellation of symptoms in addi-
tion to auricular malformation in the form of partial duplica-
tion being noted (Ashokan et al., 2014). In mouse embryos,
Hoxa2 expression in the neural crest is restricted to only the
second branchial arch which contributes to pinna develop-
ment, and ectopic expression of Hoxa2 in the first branchial
arch neural crest results in the recapitulation of partial
duplication of the pinna, a characteristic finding in Golden-
har Syndrome (Minoux et al., 2013).
CNCC and Craniosynostosis
Normal skull growth occurs as the neural tissues expand
and appositional bone growth occurs at the border of the
bony plates of the skull (Fig. 1). Sutures separate the bony
plates, and normal murine suture formation requires
epithelial-mesenchymal interactions between CNCC derived
mesenchyme, as well as mesoderm-derived mesenchyme.
Generally, the more anterior portions of the murine skull
are derived from the CNCC, with the exception of the inter-
parietal bone (Noden and Trainor, 2005; Mishina and
Snider, 2014). As neural tissue growth slows the pliable
infant skull matures, and the sutures begin to fuse, leading
to the formation of the more protective adult skull. In the
event these sutures fuse prematurely, a condition known as
craniosynostosis occurs, resulting in abnormal skull growth
resulting in increased intracranial pressure (Fig. 1). The
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TABLE 1. Neurocristopathies with Potential Causes and Clinical Characteristics
Condition Causes Characteristics
Velocardiofacial syndrome 22q11.2 locus deletion Prevalence: 1: 4,000, spontaneous mutation in 90%
COMT, TBX1 Etiopathophysiology: Deletion disrupts neural crest cells during organogenesis
Other names: DiGeorge syndrome, Shprintzen syndrome, CATCH22
Key Characteristics: pharyngeal dysfunction, cardiac anomalies (most common is
ventriculoseptal defect), dysmorphic facies
Affects thymus, parathyroid, arteries to face
Hypocalcemia and subsequent epileptic events
Low set ears, micrognathia, CP (usually soft palate or submucous), velopharyngeal
insufficiency induced feeding difficulties, otitis media, immunodeficiency, vertical
maxillary excess
Cognitive/learning problems
Psychiatric illness in 10% (bipolar, schizophrenia)
Diagnosis verified by symptoms & and FISH test (genetics test)
VPI repair occurs at 3–4 years of age
Waardenburg syndrome SOX10 PAX3 Prevalence: 1:40,000
Hypopigmentation in the eyes and skin
White tuft of hair present on the anterior scalp
CHARGE syndrome CHD7 Prevalence: 1:8,500–1:10,000
Complex diagnosis based on major and minor characteristics
Facial anomalies: potential for vision problems due to coloboma of the eye and
microphthalmia, choanal atresia, increased likelihood of cranial nerve
abnormalities
Variable presentation between patients
Treacher collins syndrome TCOF1 (90%) Prevalence: 1:50,000 60% spontaneous mutation
POLR1C, POLR1D Autosomal Dominant inheritance
Other names: Mandibulofacial Dysostosis
TCOF1 (treacle protein); key role in neural crest cell proliferation
Airway compromise, hearing loss, sleep apnea (25%), delayed motor and &
speech development, CP (35%), velopharyngeal insufficiency (35%)
Facial Abnormalities: downward slanting eyes, colobomas, mandibular retrogna-
thia, midface hypoplasia, malformed, or absent ears
Dental Anomalies: tooth agenesis, enamel defects, anterior open bite, mouth
breathing, ectopic eruption
Feeding problems, language problems
Can be detected on ultrasound
Craniofacial microsomia Genetics Prevalence: 1:5000, M > F
Teratogens that cause
hematoma of arteries
of 1st & and 2nd
branchial arches
leading to vascular
problems in utero.
Other names: Hemifacial microsomia, oral-mandibular-auricular syndrome, 1st
and 2nd branchial arch syndrome
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dura mater envelops the brain and is continuous with the
calvarial periosteum at the suture. The underlying dura
mater is known to interact molecularly with the developing
suture and influence patency in rabbit models of craniosyn-
ostosis (Cooper et al., 2012; Mishina and Snider, 2014). Dura
mater formation is compromised in Wnt1-Cre/Tgfbr2fl/fl
mice, leading to skull vault anomalies (Ito et al., 2003).
These observations imply that the signaling events from
the dura mater are critically important to normal growth
and development of the calvaria as neural tissues expand.
The FGF receptor family as well as the BMP signaling
pathway is known to be involved in syndromic forms of
craniosynostosis (Table 2). Several forms of craniosynosto-
sis may occur, affecting a single suture or as part of a phe-
notypically diverse syndrome. There are several molecules
that are known to be involved in a suture-specific manner
(Roscioli et al., 2013; Fig. 1). Craniosynostosis is well
documented to occur in isolation but is also known to
present within a constellation of symptoms in syndromes
with diverse clinical presentation. For example, gain of
function mutations of receptors in the FGF pathway can
result in Crouzon syndrome, as well as the closely related
Apert syndrome (Jabs et al., 1994; Reardon et al., 1994).
Both syndromes include craniosynostosis with Apert syn-
drome also presenting with syndactyly. Pfeiffer syndrome
also presents with craniosynostosis and mutations in FGF
receptors (Ibrahimi et al., 2004). Any individual suture as
well as combinations of sutures may be affected each
with a characteristic defect in cranial morphology (Fig.
1). For example, sagittal synostosis inhibits the lateral
growth of the skull and results in an unusually narrow
skull with increased anterior–posterior dimension. Figure
2 illustrates the differences between the cranial defect
produced by either positional head deformation or cra-
niosynostosis affecting the right, lambdoid suture. The
key to differentiating these two ostensibly similar pheno-
types is by noting the finding of an ipsilateral frontal
TABLE 1. Continued
Condition Causes Characteristics
Key Characteristic: Absence or underdevelopment of structures that arise from 1st
& and 2nd pharyngeal arches
Mandible, maxilla, ear, facial soft tissue and & mm, CN VII
Disruption during first 6 weeks gestation
Vascular problem in utero affecting clotting and poor reduced facial blood supply
2nd most common congenital facial anomaly (to CLP)
Facial Abnormalities: CLP (7–22%), malar hypoplasia, facial asymmetry,
mandibular mirognathia, absence or malformed TMJ, facial clefts, facial palsy
Dental Abnormalities: delayed development, occlusal cant, impacted or missing
teeth, velopharyngeal insufficiency,
Ear abnormalities: microtia, accessory auricles, abnormal ossicles
55% also have extracranial anomalies –vertebral fusion, trismus, kidney
dysfunction, cardiac abnormalities
OMENS system used to categorize disease presentation (ocular/orbital,
mandibular, ear, nerve, soft tissue)
Goldenhar syndrome Severe form of CFM Other names: Oculoauriculovertebral syndrome (OVA)
Form of CFM with increased incidence of ear malformation.
OMENS system used to categorize disease presentation
FIGURE 1. Illustration of human and murine skull sutures and a chart of gene
mutations resulting in suture-specific craniosynostosis. This figure outlines the
diverse collection of genes that can result in craniosynostosis.
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protuberance and anteriorly displaced ear in positional
head deformation.
Premature fusion of any single suture or combinations
of sutures results in an increase of intracranial pressure,
necessitating a series of surgery to offset the pressure
increase and allow for normal growth; however, these sur-
geries are rarely fully corrective. This state of the art
allows surgeons to remove the affected suture endoscopi-
cally in some instances, thus encouraging normal growth
to resume (Sanger et al., 2014). The premature fusion of
sutures has wide reaching consequences with regards to
the other components of the craniofacial complex. Cranio-
synostosis affecting the metopic suture results in trigono-
cephaply with subsequent orbital dysmorphology. The
effect on the orbit is directly proportional to the extent of
the premature fusion (Ezaldein et al., 2014). The options
available to correct the tissue deficits remaining after sur-
gical intervention are currently limited.
Tissue Engineering with CNCC
A complete molecular catalog of the events shaping the
craniofacial complex will yield the potential for tissue
engineering approaches to regenerate tissues lost to a
variety of pathologies. The ability to easily collect and
manipulate less differentiated cells offers major advantages
for patients in terms of restoring lost tissues. In fact, these
areas are currently being investigated with a number of
possible sources found in the oral cavity (Achilleos and
Trainor, 2012). Numerous sources of purported “stem” cell
populations have been identified in the craniofacial region:
TABLE 2. Summary of Craniosynostoses with Causes and Characteristics
Condition Causes Characteristics
Positional head deformation Extrinsic factors Head usually flat on one side
Ear & and forehead on ipsilateral side are rotated forward
Frontal bossing on ipsilateral side
Flatness of forehead on opposite side
1:2,000 births
Isolated craniosynostosis Unknown Premature fusion of one or more sutures
Skull cannot expand perpendicularly to the fused suture so
excessive growth occurs in a direction parallel to the fused suture
Crouzon syndrome FGFR2 Autosomal dominant; 1:25,000–60,000
Craniosynostosis, midface hypoplasia, hypertelorism (wideset eyes),
proptosis, beak nose
Apert syndrome FGFR2 Autosomal dominant; 1:160,000
Craniosynostosis, midface hypoplasia, hypertelorism, symmetric
syndactyly, mental handicap (50%), CP (30%)
Pfeiffer syndrome FGFR1 & and 2 Autosomal dominant; 1:100,000
Craniosynostosis, broad features, cloverleaf skull, syndactyly, elbow ankylosis
Saethre-Chotzen syndrome TWIST Autosomal dominant
Craniosynostosis, broad features, syndactyly, beak nose
Carpenter syndrome RAB23, MEGF8 Autosomal Recessive
Craniosynostosis, midface hypoplasia, mental handicap, syndactyly
FIGURE 2. Diagram of positional head deformation versus lambdoid synostosis.
The ability to differentiate between similar phenotypic presentations is key.
Noting ear and frontal protuberance position is critical to differentiate these
diagnoses. Red indicates a fused suture whereas green indicates patency.
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dental pulp stem cells, stem cells from human exfoliated
deciduous teeth, stem cells from apical papilla, periodontal
ligament stem cells, as well as progenitor sources that have
been reported from the gingiva (Miura et al., 2003; Huang
et al., 2009; Xu et al., 2013). A connexin-43 enriched human
cell population isolated from periodontal ligament cells
from extracted third molars has been shown to be multipo-
tent in both in vitro culture and in vivo teratoma formation
assays (Pelaez et al., 2013). This is particularly exciting, due
to the fact that third molar extraction is routinely done and
would provide a readily accessible source of postnatal stem
cells that could be used to regenerate craniofacial tissues
lost for a variety of reasons.
It is rapidly becoming obvious that the CRISPR-Cas9
system allows multiple genes to be edited rather quickly
and their combinatorial effects assessed in a variety of set-
tings (Hsu et al., 2014). A small guide RNA molecule with
base pair complementarity to a particular locus in the
genome allows an enzyme that cleaves DNA, Cas9, to locate
and remove certain sites in the genome, or the CRISPR-
Cas9 system can be used to insert new genetic elements. It
will be informative to the field to simultaneously edit com-
binations of genes in CNCC from a variety of model organ-
isms. The continued characterization of the stem cell nature
of CNCC obtained from early mouse embryos (Ishii et al.,
2012) and relative ease in obtaining anatomically unique
CNCC populations after birth make it attractive to investi-
gate them as a relevant tool for tissue engineering. More-
over, bioinformatic approaches that identify genes and gene
networks coupled with the ability to test these networks
using CRISPR-Cas9 to simultaneously edit the proposed
genes in CNCC culture is a promising strategy to reveal the
complex molecular interplay in CNCC.
Once the gene networks are identified, many potential
avenues of treatment can be investigated. As ectomesen-
chymal tissues in the craniofacial complex are generated
by CNCC, the knowledge of which gene networks result in
lineage specification to either osteoblasts or chondrocytes
provides an avenue to pursue regenerating these tissues.
This may improve treatment options by allowing for thera-
pies where patient derived cells are collected and used to
regenerate lost bone or cartilage. In particular, one could
isolate CNCC progenitors from a patient and use the iden-
tified gene network to promote bone formation in culture.
This cultured bone could then be used to treat bone loss
due to periodontal disease. Many hurdles remain in mak-
ing this a reality, but progress is definitely being made.
Discussion
A complete understanding of CNCC behavior in terms of
the molecular events involved initially in their migration
and those that end their journey will allow for targeted
therapies involving these pathways. The wide ranging
nature of the phenotypes displayed by birth defects affect-
ing the head and neck have made ascertaining the root
cause of these defects extremely difficult. Increased ability
to manipulate the genomes of many different model organ-
isms will allow researchers to identify responsible gene
regulatory networks and eventually to intervene to either
prevent the phenotype altogether or halt its progression.
The wide range of potential research uses makes study-
ing CNCC particularly appealing. For instance, in addition to
the many advantages outlined in this review, consider the
following: given the deleterious migration of metastasizing
cancer cells which also often undergo EMT, knowing exactly
how this extensive migration of CNCC is orchestrated could
possibly be extrapolated to halt unwanted migration of
oncogenic cell populations (Rogers et al., 2013).
In light of recent reduction in the expense of bioinfor-
matics techniques coupled with their increasing power, it is
becoming feasible to check many tissues and gather a snap-
shot of the differential gene expression patterns at play in
them. This will illuminate therapeutic targets that can be
tested in model systems to translate genomic readouts into
information to treat patients. The knowledge gleaned from
these studies will not only be applicable to patients suffer-
ing from diseases directly caused by failure of CNCC but
also to those patients requiring regeneration of tissue lost
due to trauma or other disease processes.
Although CRISPR-Cas9 is a new technology with many
potential obstacles yet to be encountered, one can see
how clinically useful such a technique could be. It is not
out of reach to imagine the following scenario: a craniosy-
nostic patient undergoes endoscopic surgery to resect
their prematurely fused suture, stem cells are isolated
from the resected tissue, CRISPR-Cas9 is used to excise
the defective sequence, and the edited cells are reintro-
duced into the patient to correct the defect.
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